Key Takeaways
- Maiden call, margin reset: Q2 FY26 revenue grew 15% YoY but PAT fell to ₹46.8 cr as upfront investments in a direct European/US sales network compressed EBITDA margins to 38%.
- Tariff scare passed without damage: US customers paused briefly after August 2025 tariff announcements, then resumed ordering; management says ordering patterns are back to forecast with no significant volume or margin impact.
- The NSS bolt-on is a regulatory fast-track: Acquiring the Irish premix business cuts out a five-year approval cycle to enter the European market, and the integration playbook (Indian backend, European frontend) is already running.
- Battery materials is the long-dated option: The pCAM pilot is sampling 36+ customers and a 25,000-ton Dahej phase-one is targeted for early CY27, but meaningful revenue waits until FY28.
- What to watch next quarter: Whether the direct-sales investments start lifting margins as promised, the pace of working-capital normalization from 195 days toward 140-150, and any Q3 catch-up from tariff-deferred Q2 volumes.
The Quarter: Growth, Mix and the Margin Reset
- Topline held up, bottomline dipped: Total income grew 15% YoY in Q2 and 31% in H1, driven by sustained demand and higher volumes across both pharma food & nutrition and specialty ingredients. PAT declined to ₹46.8 cr from ₹48.7 cr a year ago because the cost of building a direct sales and warehousing presence in Europe and the US hit the P&L.
- Two-speed business model: Roughly half the business is monthly recurring orders (static categories like calcium supplements); the other half is lumpy campaign orders for specialty ingredients, where a Pfizer or Danone places a large order for a specific global site but not every quarter. Campaign timing explains part of the Q2 sequential softness.
- Gross margin returned to earth: Last year's gross margins were exceptional because raw-material price reductions were not passed through under annual contracts. FY26 contracts reset that pass-through, bringing gross margins back to the historical average of 63-64%, a level management calls comfortable to sustain.
- Capacity headroom is ample: Utilization sits at roughly 50% across all manufacturing, with the pharma food nutrition vertical at about 65% against an optimum of 70%. The upcoming Nandesari greenfield will add further volume capacity, with customer site approvals consuming the first six months of FY27 before any ramp.
Shanil Bhayani: "Since then, the customer ordering patterns have returned to the original forecast without any significant volume or margin impact."
The US Tariff Episode
- A pause, not a reset: After tariff announcements in August 2025, US customers adopted a measured, wait-and-watch procurement approach. Because Sudeep's ingredients carry high criticality but low cost contribution to end products, customers resumed ordering and many agreed to absorb the tariff impact themselves.
- Half the exposure removed: Following October 2025 guidelines, only 50% of US business is subject to the tariff; the other 50% is exempted. Some sales that would have landed in Q2 will now reflect in Q3, but management reports no significant volume or margin damage.
- Demand returning to normal: US demand is now described as back to normal levels, and the tariff assessment period is effectively behind the quarter.
NSS Acquisition: The European Accelerator
- What was bought: In May 2025, Sudeep acquired an 85% stake in Nutrition Supplies and Services (Ireland), a company with over 40 years of experience in infant and medical nutrition premixes. The majority of consolidation hit Q2, contributing roughly ₹20 cr in revenue at a ~30% EBITDA margin, with sales recorded for only four of the six months the inventory was on the books.
- The regulatory shortcut: NSS operated with select customers in select European countries but without a sales team. The acquisition cuts out the five-year approval cycle Sudeep would typically need to enter the European market, and the goal is to expand NSS PAN-Europe.
- Integration playbook is live: Serkan Celebi has been appointed MD for the European business and NSS. The strategy leverages Sudeep's Indian backend (R&D, finance, procurement) to support NSS growth, while NSS becomes a customer of Sudeep for ingredients it previously bought from European and American competitors. Sudeep is already approved with the three leading infant formula companies, which overlap with NSS's customer set.
- No historicals disclosed: Management declined to share NSS's FY25 full-year revenue and EBITDA, calling the data confidential to the acquisition.
Shanil Bhayani: "And through the acquisition, what we've done is, we've cut out the five-year approval that we would have typically needed to enter the European market."
Direct Distribution: The Margin Bet
- The strategic shift: Over the last 12-18 months, Sudeep has been building a direct sales team and warehousing capabilities in Europe and the US, moving away from a distributor network. The goal is to engage directly with customers and improve margin realization.
- Short-term cost, medium-term payoff: These upfront investments are the primary reason EBITDA margin fell from 40.9% in H1 FY25 to 37.9% in H1 FY26. Management expects the investments to start reflecting positively over the next couple of quarters.
- Margin floor, not ceiling: The business has delivered above 35% EBITDA margin for the past couple of years and management expects to maintain that going forward, though it declined to pin down a specific normalized figure when an analyst suggested 30-35%.
Battery Materials (pCAM): The Long-Dated Option
- The technology claim: Sudeep Advanced Materials has built a low-effluent process for battery-grade iron phosphate (a precursor cathode-active material for LFP batteries) that it says delivers at par or superior electrochemical performance versus Chinese technology, positioning it as the first ex-China alternative for the global LFP market.
- Where it stands today: A customer qualification pilot plant is running at 200 kg per day. Samples have been supplied to over 36 customers across key markets, predominantly the US and Korea. Work is underway to increase capacity in an existing food-grade iron phosphate line for battery-grade output, expected to come live in the next month or two.
- The commercial timeline: A 20-acre plot has been acquired in Dahej, Gujarat, for a commercial facility. Phase one of 25,000 metric tons is targeted for completion by early CY27, with meaningful revenue expected only in FY28 once the Dahej greenfield is commissioned. Total capex to reach 100,000 tons capacity will be close to ₹500 cr.
Shanil Bhayani: "So, what we have done is we have built a technology which is very low and effluent compared to the Chinese technology, still delivers at par or superior electrochemical performance that the customers need."
Balance Sheet & Working Capital
- Working capital stretched: Net working capital days stood at 195 days, reflecting the expanding global business base, recently commenced warehousing in the US and Europe, and inventory buildup to support growth. The NSS acquisition added six months of inventory but only four months of sales, further inflating the number.
- Normalization path: Management expects the cycle to moderate and sustain at approximately 140-150 days over the medium term, with inventory rotating back to historical levels over the next two quarters.
Competitive Moat
- Four barriers to entry: Management laid out the competitive stack: proprietary technology to get the functional ingredient correct, regulatory approvals (the only Indian company with USFDA approval for mineral-based ingredients and one of nine globally with a European CEP for calcium carbonate as an API), and the most critical layer, customer approvals that take 5-7 years in infant nutrition. Sudeep is the only Indian company approved to supply the three largest infant nutrition companies globally.
Shanil Bhayani: "In India today we would probably be the first and the largest doing this and apart from Sudeep in India and China there is very limited competition in this space purely because one the technology, second using the technology to get the functional ingredient correct and third is the regulatory approval and fourth but the most critical is the customer approval that you require to operate in this category."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | 26% H1 growth rate sustained for full year | FY26 |
| EBITDA margin floor | Maintain above 35% going forward | Ongoing |
| Gross margin | Sustain at historical average of 63-64% | Ongoing |
| Working capital normalization | Moderate to ~140-150 days | Medium term |
| Inventory stabilization | Rotate back to historical levels | Next two quarters |
| Direct-sales investment payoff | Start reflecting positively in margins | Next couple of quarters |
| Nandesari greenfield commissioning | Fifth facility online | Q4 FY26 |
| Nandesari revenue contribution | Majority of business from existing capacity; meaningful greenfield contribution | Second half FY27, predominantly FY28 |
| Dahej pCAM phase one | 25,000 metric tons capacity completed | Early CY27 |
| pCAM meaningful revenue | From Dahej greenfield | FY28 |
| pCAM additional pilot capacity | Existing food-grade line converted to battery grade | Next month or two |
Key Metrics
| Metric | Q2 FY26 |
|---|---|
| Total income | ₹172.8 cr, +15% YoY |
| EBITDA | ₹65.6 cr, flat YoY (vs ₹65.3 cr in Q2 FY25) |
| EBITDA margin | 38%, vs 43.3% in Q2 FY25 (per an analyst's math) |
| PAT | ₹46.8 cr, -4% YoY (vs ₹48.7 cr in Q2 FY25) |
| H1 FY26 total income | ₹302.9 cr, +31% YoY |
| H1 FY26 EBITDA margin | 37.9%, vs 40.9% in H1 FY25 |
| H1 FY26 PAT | ₹78 cr, +19% YoY |
| International revenue share | 61% of H1 FY26 revenue |
| Specialty ingredients revenue share | 60% of H1 FY26 revenue |
| Pharma, food and nutrition revenue share | 40% of H1 FY26 revenue |
| NSS revenue contribution | ~₹20 cr in Q2 |
| NSS EBITDA margin | ~30% |
| Net working capital days | 195 days as of 30 Sep 2025 |
| Net debt | ₹73 cr, net debt-to-equity 0.1x as of 30 Sep 2025 |
| Greenfield capex spent | ~₹120 cr of ₹150 cr outlay spent by Sep 2025 |
| Overall capacity utilization | ~50% across all manufacturing |
| Pharma food and nutrition capacity utilization | ~65%, with optimum of 70% |
| NSS capacity utilization | ~35% |
| Gross margin | 63%-64% historical average, Q2 returned to this level after an exceptional FY25 |
| US business subject to tariff | 50% subject to tariff, 50% exempted |
| H1 FY26 growth rate | 26% |
| Specialty ingredients CAGR since 2021 | 32% |
| R&D investment | ~2% of revenue |
| pCAM phase one capex | ~₹220 cr, including land and development |
| pCAM customer samples | Over 36 customers across US and Korea |